Telix Pharmaceuticals Limited

112 articles about Telix Pharmaceuticals Limited

• Q1 2024 Revenue and Business Update

  4/17/2024

  Telix Pharmaceuticals Limited provides an update on its revenue and operational performance for the quarter ended 31 March 2024.

• QSAM Announces Reverse Stock Split Ratio Ahead of Merger

  4/16/2024

  QSAM Biosciences, Inc. previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited pursuant to which Telix will acquire QSAM.

• TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

  4/15/2024

  Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration has granted Fast Track designation for the Company’s investigational glioma imaging product, TLX101-CDx.

• Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.

  4/11/2024

  ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.

• Appointment of Dr Darren Patti to Group Chief Operating Officer

  3/11/2024

  Telix Pharmaceuticals Limited is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer, effective 11 March 2024.

• Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

  3/4/2024

  Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc., its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

• Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

  2/26/2024

  Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC, a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas.

• Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

  2/22/2024

  Telix Pharmaceuticals Limited announces its results for the financial year ended 31 December 2023.

• Telix Announces Planned Registered Public Offering and Listing in the United States

  1/4/2024

  Telix Pharmaceuticals Limited announces that it is considering an initial public offering of American Depositary Shares representing its ordinary shares in the United States and listing on the Nasdaq Global Market.

• Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

  12/18/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (Zircaix™,[1] 89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC).

• First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent

  12/11/2023

  Telix Pharmaceuticals Limited  today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331 ) for TLX250-CDx ( 89 Zr-DFO-girentuximab).

• QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

  11/14/2023

  QSAM Biosciences Inc. has signed a non-binding term sheet with Telix Pharmaceuticals Inc., a subsidiary of Telix Pharmaceuticals Limited providing material terms for the acquisition of the Company by Telix by means of a merger.

• Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

  11/13/2023

  Telix Pharmaceuticals Limited and Paris-based Mauna Kea Technologies, announce an expansion of the IRiS Alliance[1] through a strategic €6.0 million investment to develop new hybrid pharmaceutical-device products through the combination of Telix's cancer-targeting agents with Mauna Kea's Cellvizio® surgical endomicroscopy platform.

• First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

  11/12/2023

  Telix Pharmaceuticals Limited announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen targeting radio-antibody drug conjugate therapy, TLX591.

• Telix to Present at Jefferies London Healthcare Conference 2023

  11/8/2023

  Telix Pharmaceuticals Limited advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023.

• Telix reports fourth consecutive quarter of positive operating cash flow

  10/18/2023

  Telix Pharmaceuticals Limited issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023.

• ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

  10/18/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC).

• Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

  8/23/2023

  Telix Pharmaceuticals Limited announces its financial results for the half-year ended 30 June 2023.

• First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

  8/10/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the imaging of prostate cancer using positron emission tomography (PET).

• First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma

  8/7/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the Company's investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer.